← boardnext 2026-08next 2028-01
ACIU
AC Immune SAdistress 4/10 · elevated risk$2.23-2%today-44% from 52w high
Lead: Amyloid Plaque
Revenue
pre-revenue
Liquidity
$75M
Runway
1.1 yrs
Shares 1y
0%
Price & events
-38.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
+2.3%
1W
-9.0%
1M
-24.9%
3M
-39.7%
6M
-4.7%
1Y
-39.6%
2Y
-70.1%
5Y
-58.1%
All
Overview
- Market Cap
- $226.89M
- Volume
- 6.85K
- 52 Week Range
- $2.04 – $3.99
- Total Shares
- 101.74M
- Float Shares
- 38.75M
- Short %
- 6.92%
- % Held by Insiders
- 37.90%
- % Held by Institutions
- 24.83%
- RVOL
- 0.03x
- Beta
- 1.57
Pipeline stages · 2 programs
ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 a
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optiona
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-08-31 | Phase 1 | ACI-19764 at dose A1, ACI-19764 at dose A2, ACI-19764 at dose A3 | Healthy Participants | 78 | recruiting |
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optiona | Parkinson Disease, Parkinson Disease 6, Early-Onset | — | active not recruiting |
| 2029-04 Estimated 50% readout ~2029-05-16 | Phase 1/2 | ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 a | Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-04earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+280% upside) · 4 analysts
- 2026-05-04BTIGBuy
- 2026-03-16BTIGBuy
- 2025-11-04BTIGBuy
- 2025-09-08BTIGBuy
- 2025-05-01HC Wainwright & Co.Buy
- 2025-04-03HC Wainwright & Co.Buy
Competitors — Amyloid Plaque
- none identified
Recent news
- 2026-07-14AC Immune Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock Rises - Analyst Coverage Count - dars.gov.et
- 2026-07-07AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - GlobeNewswire
- 2026-07-07AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - GlobeNewswire
- 2026-07-07AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - GlobeNewswire
- 2026-07-07AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - Yahoo Finance
- 2026-07-07AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - Yahoo Finance UK
- 2026-07-07AC Immune to present new neurodegenerative dise... - Pluang
- 2026-07-07AC Immune brings three neurodegeneration studies to AAIC 2026 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.